Investigating clinical trial samples to predict how atypical teratoid rhabdoid tumours will respond to treatment
Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.
Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Your child will usually need to spend some time in hospital during their treatment. All children and young people diagnosed with cancer are treated in one of the 21 specialist hospital centres across the UK and Ireland.
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
Optimising tyrosine kinase inhibitor therapy in newly diagnosed metastatic Ewing sarcoma
Novel biomarkers for PARP inhibitor trials for children with cancer
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis
Towards a new therapy against childhood brain cancer: How does the Zika virus kill aggressive brain tumour cells?